Drug Discovery & Development | PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from ... MarketWatch ... showing PIXUVRI's cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line ... UK's NICE Issues Final Appraisal Determination on CTI Lymphoma Drug Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In ... |
